Nutex Health (NUTX) Cash & Equivalents (2010 - 2026)

Nutex Health has disclosed Cash & Equivalents across 17 years of filings, most recently posting $207.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $207.3 million, up 144.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $207.3 million (up 144.72% YoY), and the FY2025 annual result was $185.6 million, up 356.63% from the prior year.
• Cash & Equivalents came in at $207.3 million for Q1 2026 at Nutex Health, up from $185.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $207.3 million in Q1 2026 to a low of $3.3 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $40.6 million (2024), against an average of $66.8 million.
• Peak annual rise in Cash & Equivalents reached 909.53% in 2023, while the deepest fall reached 35.77% in 2023.
• Nutex Health's Cash & Equivalents stood at $34.3 million in 2022, then slumped by 35.77% to $22.0 million in 2023, then surged by 84.71% to $40.6 million in 2024, then surged by 356.63% to $185.6 million in 2025, then gained by 11.73% to $207.3 million in 2026.
• The last three Cash & Equivalents figures came in at $207.3 million (Q1 2026), $185.6 million (Q4 2025), and $166.0 million (Q3 2025), per Business Quant data.